Shrestha Gambhir, Wei Xiaolin, Hann Katrina, Soe Kyaw Thu, Satyanarayana Srinath, Siwakoti Bhola, Bastakoti Shankar, Mulmi Rashmi, Rana Kritika, Lamichhane Nirmal
Department of Community Medicine, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu 44600, Nepal.
Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.
Trop Med Infect Dis. 2021 Apr 13;6(2):49. doi: 10.3390/tropicalmed6020049.
Cancer patients are at high risk of antibiotic resistant bacterial urinary tract infections (UTIs). In this study, we assessed the bacterial profile and antibiotic resistance among cancer patients suspected of UTI in B.P. Koirala Memorial Cancer Hospital in Nepal through a cross-sectional study with routinely collected data. All cancer patients who had a recorded urine culture between July 2018-June 2019 were included in the study. Out of 308 patients who had undergone culture, 73 (24%) of samples had bacterial growth. The most common organisms isolated were (58%), (11%) and (10%). These bacteria had undergone susceptibility testing to 27 different antibiotics in various proportions. Of the limited antibiotic testing levels, nitrofurantoin (54/66, 82%) and amikacin (30/51, 59%) were the most common. Among those tested, there were high levels of resistance to antibiotics in the "Access" and "Watch" groups of antibiotics (2019 WHO classification). In the "Reserve" group, both antibiotics showed resistance (polymyxin 15%, tigecycline 8%). Multidrug resistance was seen among 89% of the positive culture samples. This calls for urgent measures to optimize the use of antibiotics in UTI care at policy and health facility levels through stewardship to prevent further augmentation of antibiotic resistance among cancer patients.
癌症患者发生耐抗生素细菌性尿路感染(UTI)的风险很高。在本研究中,我们通过一项对常规收集数据的横断面研究,评估了尼泊尔BP柯伊拉腊纪念癌症医院疑似UTI的癌症患者的细菌谱和抗生素耐药性。2018年7月至2019年6月期间有尿液培养记录的所有癌症患者均纳入研究。在308例接受培养的患者中,73份(24%)样本有细菌生长。分离出的最常见微生物为大肠埃希菌(58%)、肺炎克雷伯菌(11%)和粪肠球菌(10%)。这些细菌对27种不同抗生素进行了不同比例的药敏试验。在有限的抗生素检测水平中,呋喃妥因(54/66,82%)和阿米卡星(30/51,59%)最为常见。在接受检测的患者中,抗生素“准入”和“观察”组(2019年世界卫生组织分类)的耐药水平较高。在“储备”组中,两种抗生素均显示出耐药性(多粘菌素15%,替加环素8%)。89%的阳性培养样本中出现了多重耐药性。这就需要采取紧急措施,通过管理在政策和医疗机构层面优化UTI护理中抗生素的使用,以防止癌症患者中抗生素耐药性的进一步增加。